

# Nawab Qizilbash

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/933253/publications.pdf>

Version: 2024-02-01

18  
papers

4,517  
citations

840776

11  
h-index

940533

16  
g-index

20  
all docs

20  
docs citations

20  
times ranked

8911  
citing authors

#	ARTICLE	IF	CITATIONS
1	Body-mass index and cause-specific mortality in 900â€”000 adults: collaborative analyses of 57 prospective studies. <i>Lancet</i> , The, 2009, 373, 1083-1096.	13.7	3,779
2	BMI and risk of dementia in two million people over two decades: a retrospective cohort study. <i>Lancet Diabetes and Endocrinology</i> ,the, 2015, 3, 431-436.	11.4	343
3	Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 485-492.	1.9	93
4	Association of anthropometry and weight change with risk of dementia and its major subtypes: A meta-analysis consisting 2.8 million adults with 57 294 cases of dementia. <i>Obesity Reviews</i> , 2020, 21, e12989.	6.5	62
5	Blood cholesterol and risk of dementia in more than 1Âˆ8 million people over two decades: a retrospective cohort study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e498-e506.	4.6	53
6	Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. <i>BJU International</i> , 2008, 102, 981-986.	2.5	43
7	A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic Register of Post-authorization Studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 695-706.	1.9	30
8	Benefit-Risk Analysis of Glatiramer Acetate for Relapsing-Remitting and Clinically Isolated Syndrome Multiple Sclerosis. <i>Clinical Therapeutics</i> , 2012, 34, 159-176.e5.	2.5	26
9	A Retrospective Study of the Clinical Burden of Hospitalized All-Cause and Pneumococcal Pneumonia in Canada. <i>Canadian Respiratory Journal</i> , 2016, 2016, 1-10.	1.6	23
10	Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 601-608.	1.9	21
11	Are risk minimization measures for approved drugs in Europe effective? A systematic review. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 443-454.	2.4	21
12	Localised neuropathic pain in the primary care setting: a cross-sectional study of prevalence, clinical characteristics, treatment patterns, quality of life and sleep performance. <i>Current Medical Research and Opinion</i> , 2021, 37, 293-302.	1.9	8
13	Raised blood pressure and risk of dementia. <i>European Heart Journal</i> , 2019, 40, 785-786.	2.2	5
14	Linking process indicators and clinical/safety outcomes to assess the effectiveness of abatacept ( <i>J Immunol</i> ). <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 664-674.	1.9	3
15	Does midlife obesity really lower dementia risk? Authors' reply. <i>Lancet Diabetes and Endocrinology</i> ,the, 2015, 3, 501-502.	11.4	2
16	Pre/post effectiveness evaluation of updated additional risk minimisation measures for an orphan disease: Myozyme (alglucosidase alfa) Safety Information Packet. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 103-110.	1.9	2
17	Antipsychotic treatment patterns in Alzheimer's disease patients with agitation: a cohort study using the UK clinical practice research datalink. <i>Current Medical Research and Opinion</i> , 2022, , 1-8.	1.9	0
18	Effectiveness of Additional Risk Minimization Measures for Atezolizumab in the European Union. <i>Pharmaceutical Medicine</i> , 2021, 35, 339-351.	1.9	0